Literature DB >> 23478275

New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging.

Filipe Palavra1, Daniela Marado, Filipa Mascarenhas-Melo, José Sereno, Edite Teixeira-Lemos, Carla Cecília Nunes, Grilo Gonçalves, Frederico Teixeira, Flávio Reis.   

Abstract

OBJECTIVES: This study aimed to characterize a population of multiple sclerosis (MS) patients in terms of traditional and new cardiovascular risk factors and assess their putative correlation with clinical disease activity (evaluated by the Expanded Disability Status Scale [EDSS]).
METHODS: Thirty relapsing MS patients and 66 subjects, matched by age and sex, were enrolled in this cross-sectional study. For each subject, anthropometric data were collected and classical biochemical (including lipid profile, glucose and C reactive protein [CRP] levels) and novel markers (paraoxonase 1 [PON1] enzyme activity and contents of high-density lipoprotein [HDL] cholesterol, oxidized low-density lipoprotein [Ox-LDL], tumor necrosis factor [TNF]-alfa, vascular endothelial growth factor [VEGF] and adiponectin) were studied.
RESULTS: In patients group, 23 women and 7 men were included, aged 35.00 (28.25-40.25) years and scoring a median of 2.00 (1.50-3.13) in EDSS. Comparing with controls, the most relevant differences encountered were: increased serum triglycerides (P< 0.001), Ox-LDL (P< 0.001) as well as Ox-LDL/LDL ratio and reduced small HDL (P=0.040), accompanied by a trend to increased VEGF concentration. LDL content, especially Ox-LDL, showed positive and significant correlation with EDSS (r=0.458; P=0.011) and VEGF (r=0.453; P=0.014).
CONCLUSIONS: MS patients presented a profile of early CV risk, being Ox-LDL contents a putative good marker and having correlation with the clinical activity of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478275      PMCID: PMC3809749          DOI: 10.3233/DMA-130979

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  15 in total

1.  Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

Authors:  Shreya Mukhopadhyay; Kelly Fellows; Richard W Browne; Prachi Khare; Sandhya Krishnan Radhakrishnan; Jesper Hagemeier; Bianca Weinstock-Guttman; Robert Zivadinov; Murali Ramanathan
Journal:  Mult Scler       Date:  2016-09-28       Impact factor: 6.312

2.  Cardiovascular Dysfunction in Multiple Sclerosis.

Authors:  Raluca Ileana Mincu; Lucia Stefania Magda; Maria Florescu; Andreea Velcea; Sorina Mihaila; Diana Mihalcea; Bogdan O Popescu; Adela Chiru; Cristina Tiu; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2015-09

3.  Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia.

Authors:  Yifei Dong; Charlotte D'Mello; William Pinsky; Brian M Lozinski; Deepak K Kaushik; Samira Ghorbani; Dorsa Moezzi; Dennis Brown; Francisca C Melo; Stephanie Zandee; Tina Vo; Alexandre Prat; Shawn N Whitehead; V Wee Yong
Journal:  Nat Neurosci       Date:  2021-02-18       Impact factor: 28.771

4.  Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid.

Authors:  Filipa Mascarenhas-Melo; Filipe Palavra; Daniela Marado; José Sereno; Edite Teixeira-Lemos; Isabel Freitas; Maria Isabel-Mendonça; Rui Pinto; Frederico Teixeira; Flávio Reis
Journal:  ScientificWorldJournal       Date:  2013-11-04

Review 5.  Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Francesco Girolamo; Cristiana Coppola; Domenico Ribatti; Maria Trojano
Journal:  Acta Neuropathol Commun       Date:  2014-07-22       Impact factor: 7.801

6.  Improvement of oxidative and metabolic parameters by cellfood administration in patients affected by neurodegenerative diseases on chelation treatment.

Authors:  Alessandro Fulgenzi; Rachele De Giuseppe; Fabrizia Bamonti; Maria Elena Ferrero
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

7.  Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.

Authors:  Winde Jorissen; Tim Vanmierlo; Inez Wens; Veerle Somers; Bart Van Wijmeersch; Jeroen F Bogie; Alan T Remaley; Bert O Eijnde; Jerome J A Hendriks
Journal:  Int J Mol Sci       Date:  2018-01-08       Impact factor: 5.923

8.  Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL.

Authors:  Winde Jorissen; Elien Wouters; Jeroen F Bogie; Tim Vanmierlo; Jean-Paul Noben; Denis Sviridov; Niels Hellings; Veerle Somers; Roland Valcke; Bart Vanwijmeersch; Piet Stinissen; Monique T Mulder; Alan T Remaley; Jerome J A Hendriks
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

9.  Relation Between the Novel Marker Monocyte to High-Density Lipoprotein Cholesterol Ratio and Severity in Multiple Sclerosis.

Authors:  Ersin Kasım Ulusoy; Ömer Faruk Bolattürk; Mehmet Fatih Göl
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

10.  Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin.

Authors:  Filipa Mascarenhas-Melo; José Sereno; Edite Teixeira-Lemos; Daniela Marado; Filipe Palavra; Rui Pinto; Petronila Rocha-Pereira; Frederico Teixeira; Flávio Reis
Journal:  Mediators Inflamm       Date:  2013-10-24       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.